Surveillance Of CA-125 Alone May Be Used To Detect Disease Progression Of Advanced Ovarian Cancer Being Treated With Olaparib And Bevacizumab, Trial Results Show

Cancer Network (3/31, Seymour) reports, “In patients with an abnormal CA-125 level at the beginning of frontline maintenance therapy, surveillance of CA-125 alone may be used to detect disease progression of advanced ovarian cancer being treated with olaparib (Lynparza) and bevacizumab (Avastin).” The “results were taken from an analysis of the phase 3 PAOLA-1 trial (NCT02477644) and were presented at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer.”